JP2008518978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518978A5 JP2008518978A5 JP2007539437A JP2007539437A JP2008518978A5 JP 2008518978 A5 JP2008518978 A5 JP 2008518978A5 JP 2007539437 A JP2007539437 A JP 2007539437A JP 2007539437 A JP2007539437 A JP 2007539437A JP 2008518978 A5 JP2008518978 A5 JP 2008518978A5
- Authority
- JP
- Japan
- Prior art keywords
- arg
- lys
- seq
- gly
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 2
- FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- CZVQSYNVUHAILZ-UWVGGRQHSA-N His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 CZVQSYNVUHAILZ-UWVGGRQHSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH18092004 | 2004-11-02 | ||
| CH1809/04 | 2004-11-02 | ||
| PCT/CH2005/000638 WO2006047900A2 (de) | 2004-11-02 | 2005-11-01 | Neue topisch anwendbare wirkstoffe gegen mimische und alterabedingt falten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008518978A JP2008518978A (ja) | 2008-06-05 |
| JP2008518978A5 true JP2008518978A5 (enExample) | 2008-10-16 |
| JP5006789B2 JP5006789B2 (ja) | 2012-08-22 |
Family
ID=35841896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539437A Expired - Lifetime JP5006789B2 (ja) | 2004-11-02 | 2005-11-01 | 表情皺及び加齢による皺に対する新規な局所適用剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7964630B2 (enExample) |
| EP (1) | EP1809652B1 (enExample) |
| JP (1) | JP5006789B2 (enExample) |
| KR (1) | KR101227301B1 (enExample) |
| CN (1) | CN101061134B (enExample) |
| AT (1) | ATE466867T1 (enExample) |
| BR (1) | BRPI0517917B1 (enExample) |
| CA (1) | CA2584643C (enExample) |
| DE (1) | DE502005009544D1 (enExample) |
| ES (1) | ES2345667T3 (enExample) |
| PL (1) | PL1809652T3 (enExample) |
| WO (1) | WO2006047900A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100240977A1 (en) * | 2007-06-20 | 2010-09-23 | Andreas Caduff | Method for measuring the response of a tissue to an electromagnetic field |
| AU2009215436A1 (en) | 2008-02-19 | 2009-08-27 | Myocept Inc. | Postsynaptically targeted chemodenervation agents and their methods of use |
| WO2010003861A1 (en) * | 2008-07-08 | 2010-01-14 | Unilever Plc | Antiperspirant products |
| EP2143418A1 (en) | 2008-07-08 | 2010-01-13 | Unilever PLC | Antiperspirant compositions |
| EP2456457B1 (en) | 2009-07-24 | 2014-10-22 | Lipotec, S.A. | Compounds which inhibit muscle contraction |
| JP4666537B1 (ja) * | 2010-01-21 | 2011-04-06 | 株式会社資生堂 | しわ改善用美容セット並びにこれを使用する美容方法 |
| US10149812B2 (en) | 2012-04-13 | 2018-12-11 | Activen | Cosmetic composition comprising a muconopeptide |
| ES2678793T3 (es) | 2012-04-13 | 2018-08-17 | Activen | Composición cosmética que comprende un muconopéptido |
| RU2524428C1 (ru) * | 2013-01-21 | 2014-07-27 | Общество с ограниченной ответственностью "Синейро" | Пептиды и их производные, взаимодействующие с никотиновым ацетилхолиновым рецептором и пригодные для использования в косметологии против мимических и возрастных морщин |
| CN103570804B (zh) * | 2013-09-11 | 2015-04-15 | 深圳市维琪医药研发有限公司 | 一种具皮肤活性的多肽的合成方法 |
| CA2928526A1 (en) | 2013-11-01 | 2015-05-07 | Spherium Biomed S.L. | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents |
| RU2551276C1 (ru) * | 2014-02-03 | 2015-05-20 | Закрытое Акционерное Общество "Фарм-Синтез" | Способ получения диацетата трипептида |
| US9649266B2 (en) * | 2014-05-01 | 2017-05-16 | Anterios, Inc. | Methods to treat, prevent, and improve skin conditions |
| CN104327155A (zh) * | 2014-10-20 | 2015-02-04 | 张嘎 | 一种含有15n—l—脯氨酸残基的三肽型减皱化合物及其制备方法和应用 |
| CN104478991B (zh) * | 2014-12-10 | 2018-06-19 | 深圳市维琪医药研发有限公司 | 一种新型多肽化合物及其制备方法和其医药应用 |
| KR101710486B1 (ko) * | 2015-01-05 | 2017-02-28 | 주식회사 앤코스메슈 | 올리고펩타이드 유도체 및 이를 포함하는 주름개선용 조성물 |
| CN104592348A (zh) * | 2015-01-16 | 2015-05-06 | 张嘎 | 一种含有3,4-脱氢-l-脯氨酸残基的三肽减皱化合物及其制备方法和应用 |
| WO2017102588A1 (en) * | 2015-12-16 | 2017-06-22 | Dsm Ip Assets B.V. | Novel use |
| KR102706016B1 (ko) * | 2015-12-16 | 2024-09-13 | 디에스엠 아이피 어셋츠 비.브이. | 신규한 용도 |
| CN112010772A (zh) * | 2016-01-26 | 2020-12-01 | 赵鸣 | 5-氨基酮戊酸及其衍生物的盐化合物和应用 |
| CN106038385A (zh) * | 2016-06-08 | 2016-10-26 | 广州市创美时美容化妆品有限公司 | 一种刺激胶原蛋白生成抵抗皱纹的化妆品组合物 |
| CN107936108A (zh) * | 2017-12-05 | 2018-04-20 | 陕西慧康生物科技有限责任公司 | 一种类蛇毒三肽的液相合成方法 |
| CN107857797A (zh) * | 2017-12-07 | 2018-03-30 | 陕西慧康生物科技有限责任公司 | 一种类蛇毒三肽的液相片段合成方法 |
| ES2937382T3 (es) | 2018-02-27 | 2023-03-28 | Lipotrue S L | Péptidos y composiciones para uso en cosmética y medicina |
| KR102724873B1 (ko) * | 2018-05-24 | 2024-11-04 | 디에스엠 아이피 어셋츠 비.브이. | 프롤린 유도체의 신규한 용도 |
| CN118561963A (zh) | 2018-10-16 | 2024-08-30 | 格罗制药公司 | 烟碱乙酰胆碱受体肽拮抗剂芋螺毒素组合物及相关方法 |
| CN113045623A (zh) * | 2019-12-27 | 2021-06-29 | 深圳翰宇药业股份有限公司 | 一种蛇毒肽syn-ake的液相合成方法 |
| CN110950926B (zh) * | 2019-12-31 | 2020-10-16 | 山东济肽生物科技有限公司 | 类蛇毒三肽的液相合成方法 |
| CN114369139B (zh) * | 2020-10-14 | 2024-04-19 | 成都泰莱康科技有限公司 | 类蛇毒三肽的制备方法 |
| US11771637B2 (en) | 2021-01-22 | 2023-10-03 | The Procter & Gamble Company | Skin care composition and method of using the same |
| US11571378B2 (en) | 2021-01-22 | 2023-02-07 | The Procter & Gamble Company | Skin care composition and method of using the same |
| CN113693964B (zh) * | 2021-08-16 | 2023-03-24 | 深圳市维琪医药研发有限公司 | 肽衍生物在制备用于皮肤修复紧致的组合物中的新用途 |
| CN114380887A (zh) * | 2021-12-09 | 2022-04-22 | 深圳翰宇药业股份有限公司 | 一种类蛇毒三肽的液相片段合成方法 |
| WO2025162944A2 (en) * | 2024-01-29 | 2025-08-07 | Dsm Ip Assets B.V. | Novel compounds |
| WO2025170081A1 (en) | 2024-02-05 | 2025-08-14 | L'oreal | Stabilization of composition comprising polyhydroxy acid, beta-hydroxy acid and peptide with polyol |
| FR3160325A3 (fr) | 2024-03-19 | 2025-09-26 | L'oreal | Stabilisation d'une composition comprenant un polyhydroxyacide, un bêta-hydroxyacide et un peptide avec du polyol |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966701A (en) * | 1973-11-07 | 1976-06-29 | The Dow Chemical Company | Fibrinogen peptide derivatives |
| US4563305A (en) * | 1981-01-07 | 1986-01-07 | University Of Miami | Radiolabelled substrates for assaying mammalian enzymes |
| US7408027B1 (en) * | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| AU2334897A (en) | 1996-03-18 | 1997-10-10 | Regents Of The University Of California, The | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
| ES2160485B1 (es) * | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
-
2005
- 2005-11-01 US US11/718,496 patent/US7964630B2/en active Active
- 2005-11-01 BR BRPI0517917-3A patent/BRPI0517917B1/pt active IP Right Grant
- 2005-11-01 PL PL05796353T patent/PL1809652T3/pl unknown
- 2005-11-01 EP EP05796353A patent/EP1809652B1/de not_active Expired - Lifetime
- 2005-11-01 KR KR1020077011046A patent/KR101227301B1/ko not_active Expired - Lifetime
- 2005-11-01 ES ES05796353T patent/ES2345667T3/es not_active Expired - Lifetime
- 2005-11-01 DE DE502005009544T patent/DE502005009544D1/de not_active Expired - Lifetime
- 2005-11-01 WO PCT/CH2005/000638 patent/WO2006047900A2/de not_active Ceased
- 2005-11-01 JP JP2007539437A patent/JP5006789B2/ja not_active Expired - Lifetime
- 2005-11-01 CA CA2584643A patent/CA2584643C/en not_active Expired - Lifetime
- 2005-11-01 CN CN2005800393599A patent/CN101061134B/zh not_active Expired - Lifetime
- 2005-11-01 AT AT05796353T patent/ATE466867T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518978A5 (enExample) | ||
| Gentilucci et al. | Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization | |
| Kimura et al. | KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine | |
| JP2013511554A5 (enExample) | ||
| JP2013155195A5 (enExample) | ||
| JP2013500990A5 (enExample) | ||
| RU2017118326A (ru) | Бициклические пептидные лиганды, специфичные для мт1-ммр | |
| JP2013533864A5 (enExample) | ||
| JP2002530430A (ja) | C型肝炎ウイルスns3プロテアーゼ阻害用の医薬組成物 | |
| JP2007500747A5 (enExample) | ||
| JP2013511553A5 (enExample) | ||
| JP2013540102A5 (enExample) | ||
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| RO115355B1 (ro) | Derivati de aminoacizi | |
| HRP20161614T1 (hr) | Terapijska sredstva za smanjenje razina paratiroidnog hormona | |
| JP2014530868A (ja) | ペプチドミメティック大環状化合物 | |
| JP2014512366A5 (enExample) | ||
| DK2697246T3 (en) | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF | |
| SK11242002A3 (sk) | Zlúčenina, spôsob prípravy zlúčeniny, farmaceutický prostriedok a spôsob liečenia rakoviny | |
| WO2013089241A1 (ja) | Fmoc基の除去方法 | |
| JP2006505621A5 (enExample) | ||
| JP2006505555A5 (enExample) | ||
| JP2008520658A5 (enExample) | ||
| JP2016536372A5 (enExample) | ||
| Hruby et al. | Design of novel synthetic peptides including cyclic conformationally and topgraphically constrained analogs |